Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals

Gregory M. Lucas, Yuezhou Jing, Mark Sulkowski, Alison G. Abraham, Michelle M. Estrella, Mohamed G. Atta, Derek M. Fine, Marina B. Klein, Michael J. Silverberg, M. John Gill, Richard D. Moore, Kelly A. Gebo, Timothy R. Sterling, Adeel A. Butt, Gregory D. Kirk, Constance A. Benson, Ronald J. Bosch, Ann C. Collier, Stephen Boswell, Chris GrassoKen Mayer, Robert S. Hogg, Richard Harrigan, Julio Montaner, Angela Cescon, John T. Brooks, Kate Buchacz, John T. Carey, Benigno Rodriguez, Michael A. Horberg, Jennifer E. Thorne, James J. Goedert, Lisa P. Jacobson, Sean B. Rourke, Ann Burchell, Anita R. Rachlis, Puerto Rico, Robert F. Hunter-Mellado, Angel M. Mayor, Steven G. Deeks, Jeffrey N. Martin, Pragna Patel, Michael S. Saag, Michael J. Mugavero, James Willig, Joseph J. Eron, Sonia Napravnik, Mari M. Kitahata, Heidi M. Crane, Amy C. Justice, Robert Dubrow, David Fiellin, David Haas, Sally Bebawy, Megan Turner, Stephen J. Gange, Kathryn Anastos, Rosemary G. McKaig, Aimee M. Freeman, Carol Lent, Stephen E. Van Rompaey, Eric Webster, Liz Morton, Brenda Simon, Keri N. Althoff, Bryan Lau, Jinbing Zhang, Jerry Jing, Elizabeth Golub, Shari Modur, David B. Hanna, Peter Rebeiro, Cherise Wong, Adell Mendes

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Background. The role of active hepatitis C virus (HCV) replication in chronic kidney disease (CKD) risk has not been clarified.Methods. We compared CKD incidence in a large cohort of HIV-infected subjects who were HCV seronegative, HCV viremic (detectable HCV RNA), or HCV aviremic (HCV seropositive, undetectable HCV RNA). Stages 3 and 5 CKD were defined according to standard criteria. Progressive CKD was defined as a sustained 25% glomerular filtration rate (GFR) decrease from baseline to a GFR < 60 mL/min/1.73 m 2. We used Cox models to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).Results. A total of 52 602 HCV seronegative, 9508 HCV viremic, and 913 HCV aviremic subjects were included. Compared with HCV seronegative subjects, HCV viremic subjects were at increased risk for stage 3 CKD (adjusted HR 1.36 [95% CI, 1.26, 1.46]), stage 5 CKD (1.95 [1.64, 2.31]), and progressive CKD (1.31 [1.19, 1.44]), while HCV aviremic subjects were also at increased risk for stage 3 CKD (1.19 [0.98, 1.45]), stage 5 CKD (1.69 [1.07, 2.65]), and progressive CKD (1.31 [1.02, 1.68]).Conclusions. Compared with HIV-infected subjects who were HCV seronegative, both HCV viremic and HCV aviremic individuals were at increased risk for moderate and advanced CKD.

Original languageEnglish (US)
Pages (from-to)1240-1249
Number of pages10
JournalJournal of Infectious Diseases
Issue number8
StatePublished - Oct 15 2013
Externally publishedYes


  • HIV
  • chronic kidney disease
  • cohort study
  • glomerular filtration rate
  • hepatitis C RNA
  • hepatitis C virus
  • injection drug use

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals'. Together they form a unique fingerprint.

Cite this